Fundz

Beacon Biosignals Raises $27 Million Series A Led By General Catalyst To Scale Its Eeg Neurobiomarker Discovery Platform

PRIVATENov 08, 2021

Amount Raised

$27 Million

Round Type

Series A

BostonInformation TechnologySoftware

Description

Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M Series A financing led by General Catalyst and with participation from Casdin Capital. Proceeds will be used to scale Beacon's computational biomarker discovery platform and address the massive unmet need for quantitative clinical trial endpoints, safety tools, and computational diagnostics for neurology, psychiatry, and sleep medicine.

Who to call at Beacon Biosignals, and when

A new round usually means Beacon Biosignals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Beacon Biosignals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Beacon Biosignals, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Beacon Biosignals

Location

80 REVERE ST., #10

Boston, Massachusetts, United States

About

Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through novel machine learning algorithms, large datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Beacon Biosignals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

4 contacts
Verified contactsJacob D., Co-Founder and CEO hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Beacon Biosignals's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Beacon Biosignals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.